Investigators	Title	Agency	Years funded	Total awarded	2019- 2020	BHI Theme
<u>Abdalla A</u>	ASCEPT-PAGANZ 2019 Joint Scientific Meeting Travel Funding	The Hospital Research Foundation (THRF) Group	2019	\$3,600.00	\$3,600.00	Drug and Vaccine Development
Ackland S, Jameson M, Ngan S, Spry N, Stevenson A, <u>Price T</u> , Espinoza D, Frizelle F, Kemp R, Pearse M	The SPAR Trial: a randomised placebo- controlled phase 2 trial of simvastatin with preoperative chemoradiation for rectal cancer	Cancer Institute NSW	2017-2019	\$449,488.00	\$0.00	Cancer
Appleton S, Adams R, Beltrame J	Broken Sleep – Broken Heart? Longitudinal follow-up of cardiovascular and cognitive outcomes in middle aged and older men in North-West Adelaide	THRF Group	2018-2021	\$140,000.00	\$70,000.00	Chronic Disease: Cardiovascular Disease
<u>Beltrame J, Tavella R</u> , Spertus J, Arstall M, Worthley M, Chew D	Value-Based Healthcare in Elective Coronary Stenting	NHMRC (THRF Group as a partner, \$200,000)	2017-2021	\$2,440,223.00	\$326,499.00	Cardiovascular Disease
<u>Beltrame J</u> , <u>Zeitz C</u> , Lindahl B	Potential mechanisms and treatment of post-infarct Angina in patients with Myocardial Infarction in Non-Obstructive Coronary Arteries (MINOCA)	THRF Group	2017-2021	\$750,000.00	\$200,000.00	Cardiovascular Disease
Bennett C	American Rhinological Society Meeting Travel Funding	THRF Group	2019	\$4,410.00	\$4,410.00	Inflammatory Disease
Boyd M, <u>Schubert KO</u> , <u>Clark SR</u> , Gail M, Harding D, McMichael G, Baune B, Beckwith A, Shaw D, Tse E	Epclusa (sofosbuvir/velpatasvir) in people living with severe, enduring mental illness and chronic viral hepatitis C infection	Gilead Sciences		\$951,122.25	\$30,000.00	Clinical Sciences, Health Services and Population Health
<u>Bryant R</u>	Ferring IBD Clinician Establishment Award (FICE)	Gastroenterological Society of Australia (GESA)	2018-2020	\$60,000.00	\$20,000.00	Inflammatory Disease
Bryant R	Gastrointestinal ultrasound project- validation and score	Janssen			\$50,000.00	Inflammatory Disease
<u>Chong CR</u>	Novel strategy to prevent cardiovascular complications in diabetes: the role of poly (ADP-ribose) polymerase-1 inhibition	NHMRC	2019-2022	\$327,192.00	\$99,975.00	Cardiovascular Disease
Chong CR, Horowitz J, Chirkov Y	For a novel strategy for cardiovascular protection in type 2 diabetes	Diabetes SA	2020-2021	\$100,000.00	\$50,000.00	Cardiovascular Disease

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
<u>Clark SR</u> , Toben C, Jawahar C, Symon J, Mills N	To Investigate the Association of Complement, Oxidative And Inflammatory Markers And BDNF With Cognitive And General Function In Chronic Psychosis	2019 RAH Research Committee	2019-2020	\$40,242.00	\$5,032.00	Clinical Sciences, Health Services and Population Health
<u>Clark SR</u>	Transcranial Magnetic Stimulation and EEG equipment	Health Services Charitable Gifts Board	2018-2019	\$93,249.00	\$93,249.00	Clinical Sciences, Health Services and Population Health
<u>Clark SR</u> , Toben C, Baune BT	Patterns of gene expression in chronic psychosis associated with cognitive and general function	2018 RAH Research Committee	March 2017 - June 2019	\$49,888.00	\$49,888.00	Clinical Sciences, Health Services and Population Health
Condina M, Klinger-Hoffmann M, Plush S, Hoffman P, <u>Licari G</u> , <u>Pasupathy S,</u> <u>Beltrame J, Tavella R</u>	Is it dangerous to be different? Discovering mechanisms of patients with Myocardial Infarction with nonobstructive Coronary Arteries (MINOCA)	University of South Australia	2019-2020		\$38,012.00	Cardiovascular Disease
Costello S	FMT service and research support	Janssen			\$60,000.00	Inflammatory Disease
<u>Datta Gupta A</u>	A Randomized Placebo Controlled Double Blind Trial of Post Stroke Lower Limb Spasticity Using Botulinum Toxin A (BoNTA)	Allergan plc	2018-2021	\$80,000.00	\$26,667.00	Ageing
<u>Datta Gupta A</u>	Efficacy of Botulinium Toxin A on walking and quality of life in post-stroke lower limb spasticity - a randomized double bind placebo controlled study	THRF Group	2018-2021	\$105,000.00	\$35,000.00	Ageing
Deane A, Finfer S, Guyatt G, Billot L, Venkatesh B, Cook D, Chapman M, Myburgh J, <u>Peake SL (AI)</u>	Re-EValuating the Inhibition of Stress Erosions (REVISE): Gastrointestinal bleeding prophylaxis in ICU.	NHMRC	2017-2021	\$3,031,547.00	\$0.00	Clinical Sciences, Health Services and Population Health
Dollard J	1st World Congress on Falls and Postural Stability Travel Funding	THRF Group	2019	\$4,070.00	\$4,070.00	Ageing
Eldredge T	Surgical Research Society of Australasia Annual Conference Travel Funding	THRF Group	2019	\$770.00	\$770.00	Clinical Sciences, Health Services and Population Health
Evdokiou A	New Immunotherapeutic approaches targetting incompletely resected or inoperable tumours	THRF Group	2019-2021	\$750,000.00	\$375,000.00	Cancer
<u>Evdokiou A</u>	New Immunotherapeutic approaches targetting incompletely resected or inoperable tumours	THRF Group	2017-2020	\$255,000.00	\$85,000.00	Cancer

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
Evdokiou A	New Immunotherapeutic approaches targetting incompletely resected or inoperable tumours	THRF Group	2020-2021	\$102,000.00	\$0.00	Cancer
Evdokiou A	New Immunotherapeutic approaches targetting incompletely resected or inoperable tumours	The University of Adelaide	2018-2021	\$150,000.00	\$50,000.00	Cancer
<u>Fenix K</u>	Using Tissue-Resident T cells to develop new prognostics and treatments against bowel cancer	THRF Group	2018-2021	\$240,000.00	\$120,232.00	Clinical Sciences, Health Services and Population Health
<u>Fenix K</u>	Preclinical assessment of a patient derived cellular immunotherapy for metastatic colorectal cancer	Tour de Cure	2020	\$5,000.00	\$2,500.00	Clinical Sciences, Health Services and Population Health
<u>Fenix K</u> , <u>Maddern G</u>	Construction of the SA Liver Tissue-Biobank (SALT) for discovery and development of prognostic biomarkers of colorectal cancer liver metastasis	THRF Group	2019-2020	\$100,000.00	\$80,000.00	Clinical Sciences, Health Services and Population Health
Fitridge R, Bursill C, Nicholls S	Evaluation of the topical application of high-density lipoproteins on wound healing in patients with diabetic foot ulcers: a phase 1/2 clinical trial	THRF Group	2020-2021	\$250,000.00	\$0.00	Cardiovascular Disease
Forster S, Lawley T, <u>Costello S</u>	Characterisation of mobile antimicrobial resistance in the human gastrointestinal microbiota	NHMRC	2019-2022	\$878,108.00	\$50,000.00	Inflammatory Disease
<u>Gowans E, Wijesundara D, Maddern G</u>	The protective efficacy of cytolytic DNA vaccine for HCV in marmosets: a step towards human clinical trials (Test the protective efficacy of a HCV DNA vaccine in an animal model)	THRF Group	2019-2020	\$100,000.00		Drug and Vaccine Development; Clinical Sciences, Health Services and Population Health
<u>Grubor-Bauk B</u>	Zika virus: Neutralizing the menace of Zika virus	THRF Group	2020-2022	\$480,000.00	\$80,000.00	Drug and Vaccine Development
<u>Grubor-Bauk B</u>	Research Support Fellowship	THRF Group	2019	\$30,000.00	\$15,000.00	Drug and Vaccine Development
<u>Grubor-Bauk B</u>	International Society for Vaccines Congress 2019	THRF Group	2019	\$3,000.00	\$3,000.00	Drug and Vaccine Development
<u>Grubor-Bauk B</u>	Research Support Fellowship	The University of Adelaide	2019	\$30,000.00	\$15,000.00	Drug and Vaccine Development

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
<u>Grubor-Bauk B</u> , Barry S, Reddi B, Shaw D	COVID-19 SA	THRF Group	2020-2022	\$150,000.00	\$0.00	Drug and Vaccine Development
<u>Grubor-Bauk B</u> , Prow N, Robertson S, Hayball J	Maternal Immunisation with a novel Zika Vaccine to protect offspring from congenital Zika Syndrome	Channel 7 Children's Research Foundation	2020	\$100,000.00	\$50,000.00	Drug and Vaccine Development
<u>Grubor-Bauk B</u> , Prow N, Robertson S, Hayball J	Maternal Immunisation with a novel Zika Vaccine to protect offspring from congenital Zika Syndrome	THRF Group	2020	\$102,000.00	\$51,000.00	Drug and Vaccine Development
<u>Grubor-Bauk B</u> , <u>Wijesundara WK</u> , <u>Gowans EJ</u>	A novel vaccine against Zika virus	The University of Adelaide/ THRF Group	2015-2019	\$573,259.00	\$100,000.00	Drug and Vaccine Development
Grzeskowiak L, Amir L, Smithers L, Jacobs S <u>, Ingman W</u> , Grivell R	OPTimising Mothers' Own Milk supply in the neonatal unit – enhancing breast milk supply with Domperidone in mothers of preterm infants (OPTIMOM-D)	NHMRC	2019-	\$980,692.00	\$300,000.00	Cancer
<u>Hamilton-Bruce A, Koblar S, Jannes J,</u> Kleinig T	FAST-IT - Find A Simple Test In TIA (Transient Ischaemic Attack) – Proteomics biomarker project	Health Services Charitable Gifts Board	2020-2021	\$12,500.00	\$0.00	Chronic Disease
<u>Hamilton-Bruce MA</u> , <u>Koblar S</u> , Young J, Hazel S	DOgSS - Dogs Offering Support after Stroke	THRF Group	2020-2022	\$15,000.00	\$3,750.00	Chronic Disease
<u>Hamilton-Bruce MA</u> , Noschka E, <u>Koblar</u> <u>S, Jannes J</u> , Kleinig T	FAST-IT - Find A Simple Test In TIA (Transient Ischaemic Attack) – Lipidomics biomarkers	Health Services Charitable Gifts Board	2020-2021	\$7,500.00	\$0.00	Chronic Disease
<u>Hillier S, Kleinig T, Koblar S, Jannes J</u> , Khadka J, Dixon K, Martin B, <u>Hamilton-</u> <u>Bruce A, Milton A</u>	Acting fast to increase time-critical stroke treatments to all South Australians	MRFF (via South Australian Academic Health Science and Translation Centre)	2018-2019	\$196,000.00	\$49,000.00	Chronic Disease
<u>Hodge S, Zalewski P</u>	Exploiting increased autophagy in bronchial epithelial cells: a new therapeutic approach for COPD	NHMRC	2016-2018	\$745,391.00	\$120,694.00	Cardiovascular Disease
Holliday E, Attia J, Thijs V, <u>Koblar S</u> , Sturm J, Maguire J, Lincz L	Helping stroke physicians choose who to thrombolyse – the "Targeting Optimal Thrombolysis Outcomes" (TOTO) study.	NHMRC	2015-2019	\$1,073,140.00	\$107,314.00	Chronic Disease

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
Holmes A	Postpartum infections: development of novel prevention and treatment strategies for postpartum vaginal and perineal infections	THRF Group	2020-2022	\$152,000.00	\$38,000.00	Drug and Vaccine Development
Ingman W	Towards zero deaths from breast cancer	THRF Group	2019-2022	\$750,000.00	\$250,000.00	Cancer
Jasper U	Evaluating the impact of a co-created video amongst hospitalised older people and their carers on knowledge to reduce sedentary behaviour	Australian Association of Gerontology	2020	\$7,000.00	\$7,000.00	Ageing
<u>Jesudason D</u> , <u>Meyer E</u> , <u>Roberts M</u> , <u>Thiruvenkatarajan V</u> , <u>Khan MS</u>	Addressing life threatening ketoacidosis associated with sodium-glucose transporter-2 inhibitors and key antidiabetic medicines	Diabetes SA	2020	\$100,000.00	\$0.00	Chronic Disease; Drug and Vaccine Development
<u>Kao S</u>	American Rhinological Society Meeting Travel Funding	THRF Group	2019	\$2,982.00	\$2,982.00	Inflammatory Disease
<u>Karatassas A</u>	Developing a hernia mesh tissue integrated index	RACS Foundation for Surgery	2019	\$10,000.00	\$5,000.00	Clinical Sciences, Health Services and Population Health
Keijzers G, McDonald S, Williams J, Fraser J <u>, Peake S</u> , Delaney A, Taylor D, Jones P, <u>Williams P</u>	Fluid Resuscitation in Emergency patients with Sepsis and Hypotension	Emergency Medicine Foundation	2018-2019	\$96,018.00	\$48,009.00	Clinical Sciences, Health Services and Population Health
<u>Koblar S, Jannes J, Hamilton-Bruce MA</u> , Kleinig T, <u>Milton A</u>	"FAST-IT" – Find A Simple Test In Transient Ischaemic Attack (TIA)-Stroke prevention and recovery studies	Health Services Charitable Gifts Board	2017-2018 (extended)	\$12,500.00	\$6,250.00	Chronic Disease
<u>Koblar S, Jannes J, Hamilton-Bruce MA,</u> Kleinig T, <u>Milton A</u>	"FAST-IT" – Find A Simple Test In Transient Ischaemic Attack (TIA)-Stroke prevention and recovery studies	THRF Group	2019-2020	\$50,000.00	\$12,500.00	Chronic Disease
<u>Koblar S, Jannes J, Hamilton-Bruce MA,</u> Kleinig T <u>, Milton A</u>	"FAST-IT" – Find A Simple Test In Transient Ischaemic Attack (TIA)-Stroke prevention and recovery studies	THRF Group	2020-2021	\$12,500.00	\$0.00	Chronic Disease
<u>Kobler S, Hamilton-Bruce A, Jannes J,</u> Kleinig T, <u>Milton A</u>	FAST-IT preclinical neuroprotection and stem cell therapy (SCT)	THRF Group	2018-2019	\$90,000.00	\$22,500.00	Chronic Disease

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
Kopsaftis Z	Augmented reality technology to reduce health service utilisation among people with COPD	SA Health e-Health Innovation Grant Program			\$50,000.00	Clinical Sciences, Health Services and Population Health
Kremer K, <u>Hamilton-Bruce A</u> , <u>Koblar S</u> , Gancheva M	Treatment of Stroke – Translational Project	THRF Group	2020	\$22,500.00	\$11,250.00	Chronic Disease
Ma L, Liang Q, <u>Hauben E</u> , <u>Fenix K</u>	Study of bioactivity of Hengshan Astragalus Shiitake as biological response modifiers in cancer therapy	Flinders Innovation Partnership Seed Grant Scheme	2019	\$10,000.00	\$5,000.00	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u>	A comprehensive video-based coaching program for continuing surgical improvement – design, efficacy assessment and clinical implementation	THRF Group	2019-2020	\$84,000.00	\$84,000.00	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u>	ASERNIP-S/ACTASM	ACT Department of Health	2010-		\$131,956	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u>	ASERNIP-S/NTASM	Northern Territory Department of Health	2010-		\$113,020	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u>	ASERNIP-S/VASM	Victorian Department of Health	2010-		\$833,427	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u>	ASERNIP-S/WAASM	Western Australia Department of Health	2010-		\$464,982	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u>	ASERNIP-S/SAAPM	South Australia Department of Health	2010-		\$457,650	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u>	ASERNIP-S/TASM	Tasmania Department of Health	2010-		\$25,334	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u>	ASERNIP-S/QASM	Queensland Department of Health	2010-		\$954,674.00	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u>	ASERNIP-S/Commonwealth Department of Health	Medical Services Advisory Committee	2009-		\$954,987.00	Clinical Sciences, Health Services and Population Health

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
<u>Maddern G</u> , <u>Fenix K</u>	Construction of the SA Liver Tissue-Biobank (SALT) for discovery and development of prognostic biomarkers of colorectal cancer liver metastasis	Cancer Council SA Beat Cancer	2019-2020	\$100,000.00	\$100,000.00	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u> , <u>Fenix K</u>	Construction of the SA Liver Tissue-Biobank (SALT) for discovery and development of prognostic biomarkers of colorectal cancer liver metastasis	THRF Group	2019-2021	\$100,000.00	\$50,000.00	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u> , <u>Granchi N</u>	A comprehensive video based coaching program for continuing surgical services improvement-design, efficacy, assessment and clinical implementation	AVANT Foundation	2018-2020	\$100,000.00	\$37,576.00	Clinical Sciences, Health Services and Population Health
<u>Maddern G</u> , Inacio M, <u>Visvanathan R</u> , Karnon J	Mobile X-ray services provided within residential aged care facilities	MRFF	2020-	\$1,970,000.00	\$40,000.00	Clinical Sciences, Health Services and Population Health; Ageing
<u>Maddern G</u> , <u>Patiniott P</u> , <u>Karatassas A</u>	Mesh tissue integration index project	Gore	2019	\$75,000.00	\$75,000.00	Clinical Sciences, Health Services and Population Health
<u>Masavuli M</u>	Hepatitis C virus (HCV) challenge in vaccinated HCV-permissive transgenic mice	THRF Group	2020-2021	\$240,000.00	\$60,000.00	Drug and Vaccine Development
<u>Masavuli M</u>	International Society for Vaccines Congress 2019 Travel Funding	THRF Group	2019	\$3,578.00	\$3,578.00	Drug and Vaccine Development
<u>Mekonnen Z</u>	48th Annual Scientific Meeting of The Australian and New Zealand Society for Immunology	THRF Group	2019	\$970.00	\$970.00	Drug and Vaccine Development
<u>Mikaeel, R</u>		Hans-Jurgan and Marianne Ohff	2020	\$5,000.00	\$5,000.00	Cancer
Moretti K	SA Prostate Cancer outcomes Registry	Movember Foundation	2019-2020	\$130,000.00	\$95,333.33	Cancer
<u>Moretti K</u> , M O'Callaghan, A Vincent, K Beckmann, D Smith, S Mark, M Frydenberg, S Evans, J Clarke, S Walsh, T Kopsaftis, M Evans, D Merry	Predicting urinary incontinence and erectile dysfunction after prostate cancer surgery	Movember Foundation	2018-2019	\$28,619.00	\$0.00	Cancer
Pasupathy S	Relates to the following project "Myocardial Infarction with Non- Obstructive Coronary Arteries (MINOCA)"	NHF	2019	\$5,000.00	\$5,000.00	Cardiovascular Disease

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
Pasupathy S	Equipment for CADOSA (Coronary angiogram database of South Australia)	NHF SADiv	2019	\$15,000.00	\$15,000.00	Cardiovascular Disease
<u>Peake SL</u> , Chapman M, Dean A, Horowitz M, Davies A, Bellomo R	The Augmented versus Routine approach to Giving Energy Trial (TARGET)	NHMRC	2015-2019	\$3,696,854.00	\$0.00	Clinical Sciences, Health Services and Population Health
<u>Peake SL</u> , Finfer S, Paterson D, Lipman J, Roberts J, Myburgh J, Roberts J, Dulhunty J	BLING III: A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients.	NHMRC	2017-2021	\$3,354,602.00	\$653,989.00	Clinical Sciences, Health Services and Population Health
<u>Peake SL</u> , Roberts J, Hopkins P, Bulitta J, Lipman J, Turnbridge J, Slavin, M, Paul S.	Centre for Redefining antibiotic use to reDUce resistanCE and prolong the lives of antibiotics (REDUCE)	NHMRC	2015-2020	\$2,224,587.00	\$431,659.00	Clinical Sciences, Health Services and Population Health
Pearson O, <u>Jesudason D</u> et al.	Translation of culturally informed diabetes training for Aboriginal Health Practitioners on Aboriginal health outcomes: a cluster randomised trial of effectiveness	MRFF	2020-2025	\$1,299,036.00	\$0.00	Chronic Disease
Polak S, Patel N, Jamei M, Clarke J, Arora S, Martins F, Salem F, Abdulla T, Barnett A, Su Y, Crouzet N, <u>Roberts MS</u>	Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations	US FDA	2018-2020		\$100,821.00	Drug and Vaccine Development
<u>Price T</u> , Holden C, Poprawski D, Roder D, Ratcliffe J,Turnbull D, Buckley E, Singhal N, Wichmann M	Does ageism prevail in access to multidisciplinary cancer care?	Cancer Council SA Beat Cancer	2019	\$134,700.00	\$67,350.00	Cancer
<u>Psaltis AJ</u> , <u>Rameznpour M</u> , <u>Vreugde S</u>	A personalised therapeutic plan for S.aureus recalcitrant CRS	Garnett Passe and Rodney Williams Memorial Foundation		\$362,363.00	\$120,788.00	Inflammatory Disease
Ramsay R, Worthley D, Heriot A, Narasimhan V, Tie J, Woods S, <u>PriceT</u> , Graham T, <u>Hewett P</u> , Grandori C	From the Stone Age to the State of the Art – Multidimensional Precision Medicine for Peritoneal Colorectal cancer	NHMRC	2019-2023	\$1,399,877.00	\$0.00	Cancer
<u>Ranasinghe I</u>	Contribution of Physician and Device to CIED Complications	HCF Research Foundation	2019	\$160,000.00	\$80,000.00	
<u>Ranasinghe I</u>	Observing Recurrent Incidence of Adverse Outcomes following HospitalisatioNs	Heart Foundation	2017-2020	\$520,000.00	\$65,000.00	

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
	(ORION)					
Ranasinghe I, Gallagher M, Scott I	Safety, effectiveness of care and resource use among Australian hospitals (SAFER HOSPITALS)	THRF Group	2018-2021	\$250,000.00	\$72,500.00	
<u>Richter K</u>	Maximising the effectiveness of antimicrobial treatments for infection control after surgery	NHMRC	2019-	\$417,192.00	\$112,149.00	Clinical Sciences, Health Services and Population Health
<u>Richter K</u>	Improving effectiveness of infection control after surgery	THRF Group	2019-2022	\$240,000.00	\$80,000.00	Clinical Sciences, Health Services and Population Health
Roberts M	Research Fellowship	NHMRC 1107356	2016-2020	\$851,980.00	\$170,396.00	Drug and Vaccine Development
Roberts M	Characterisation of critical quality attributes for semisolid topical drug products	US FDA	2014-2019	\$1,922,954.00 (1,499,500 USD)	\$183,743.00	Drug and Vaccine Development
<u>Roberts M</u> , <u>Jesudason D</u> , <u>Myers E</u> , <u>Thiruvenkatarajan V</u>	Addressing potentially life-threatening ketoacidosis associated with key antidiabetic medicines	THRF Group	2021	\$130,000.00	\$0.00	Drug and Vaccine Development; Chronic Disease
<u>Roberts M</u> , Liu X, Grice J, Mohammad Y, Medley G, Cheruvu H, Alinaghi A, van der Hoek J, Paolak S, Nikunijkumar P, Sumit A, Abdula T, Wragg K, Clarke J, Frash H, Assimov Y, Cronin M, Maibach H, Chen T, Pope K	Formulation Drug Product Quality Attributes in Dermal Physiologically-Based Pharmacokinetic Models for Topical Dermatological Drug Products and Transdermal Delivery Systems	US FDA	2018-2020	\$641,096.00 (500,000 USD)	\$321,550.00	Drug and Vaccine Development
<u>Roberts M</u> , Mohammad Y, Grice J, Namjoshi S, Laita Silva V, Benson H, Chen T, Maibach H, Roberts D, Lian G, Wu C-Y, Alinaghi A, Ladermann J, Cronin M, Assimov Y, Frash H, van der Hoek J, Xu Z, Patzelt A	Bioequivalence of topical products: elucidating the thermodynamic and functional characteristics of compositionally different topical formulations	US FDA	2018-2023	\$1,602,919.00 (1,250,000 USD)	\$367,485.00	Drug and Vaccine Development
Roberts MS	Research Support	Quality Medication Care Pty Ltd	2019-2020		\$263,500.00	Drug and Vaccine Development
Roberts MS	Contract Research	St Vincents Hospital, Melbourne	2019	\$25,000.00	\$12,500.00	Drug and Vaccine Development

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
Sallustio B, Evdokiou A, Horowitz JD	Prevention of Heart Damage During	NHMRC	2018-	\$327,214.00	\$109,071.00	Cardiovascular Disease
	Anthracycline Cancer Chemotherapy		2010	<i>\$527,21100</i>	<i>\</i> 203)072100	
Soebarto V, Pisaniello D, Zuo J, Williamson T, Hansen A, <u>Visvanathan R,</u> van Hoof J	Improving thermal conditions in housing to support ageing in place	ARC	2018-2020	\$413,000.00	\$0.00	Ageing
<u>Stallman H</u>	Improving sleep and coping in inpatients to improve clinical outcomes and reduce hospital readmissions	THRF Group	2018-2021	\$540,000.00	\$160,000.00	Chronic Disease
Symonds E, Young GP <u>.Young JP</u>	Evaluation of blood based screening tests for colorectal neoplasia: from biomarker to accurate and acceptable tests	Cancer Australia	2019-2020	\$553,196.00	\$80,000.00	Cancer
<u>Taylor D</u>	Neighbourhood accessibility: implications for frailty and healthy ageing	THRF Group	2017-2020	\$420,000.00	\$140,000.00	Ageing
<u>Thomas N</u>	A Trojan Horse Strategy for Antimicrobial Biologistics	THRF Group	2018-2021	\$540,000.00	\$180,000.00	Inflammatory Disease
<u>Thomas N</u> , Ogunniyi D, Kopecki Z, Prestidge C, Cowin A		University of South Australia	2019-2020	\$40,000.00	\$40,000.00	Inflammatory Disease
<u>Townsend A</u> , <u>Hardingham J</u> , <u>Tomita Y</u> , <u>Price T</u>	'Preclinical investigation of the efficacy of novel aquporin 1inhibitors in preventing growth and metastasis of breast cancer'	THRF Group	2020-2021	\$120,000.00	\$0.00	Cancer
<u>Townsend A, Hardingham J, Tomita Y,</u> <u>Yool A</u> , <u>Price T, Evdokiou A</u>	Preclinical investigation of the efficacy of novel aquporin 1 inhibitors in preventing growth and metastasis of breast cancer	THRF Group	2017-2020	\$225,000.00	\$85,000.00	Cancer
<u>Veale A, Kopsaftis Z</u>	Reducing asthma-related hospitalisation and mortality in South Australia	Fay Fuller Foundation /Asthma Australia			\$33,739.00	Clinical Sciences, Health Services and Population Health
<u>Visvanathan R</u>	Frailty to achieve healthy ageing	THRF Group	2016-2022	\$625,000.00	\$125,000.00	Ageing
<u>Visvanathan R</u> , Hill K, Ranasinghe D, Lange K, Wilson A	Effectiveness of an Ambient Intelligence Geriatric Management system (AmbIGeM) to prevent falls in older people in hospitals: the AmbIGeM stepped wedge randomised trial.	NHMRC	2015-2018	\$1,649,946.00		Ageing
<u>Visvanathan R</u> , Karnon J, Kitson A, Beilby J, Cameron I, Chehade M, Bell S, Feist H	Frailty Trans-Disciplinary Research To Achieve Healthy Ageing	NHMRC	2015-	\$2,301,169.00	\$319,091.00	Ageing

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
<u>Vreugde S</u> , <u>Psaltis A</u> , Prestidge C, <u>Thomas N</u>	Maximising the antimicrobial and anti- inflammatory performance of next generation therapeutics for Chronic Rhinosinusitis	NHMRC		\$767,389.00	\$232,796.00	Inflammatory Disease
<u>Vreugde S</u> , <u>Wormald PJ</u> , Parsons D, Donnelley M	A novel treatment for Non-Tuberculous Myobacteria lung infections in people with cystic fibrosis	NFMRI		\$175,000.00	\$87,500.00	Inflammatory Disease
<u>Vreugde S</u> , <u>Wormald PJ</u> , Parsons D, Donnelley M	A novel treatment for Non-Tuberculous Myobacteria lung infections in people with cystic fibrosis	THRF Group		\$30,000.00	\$15,000.00	Inflammatory Disease
Wardill H, <u>Costello S</u> , <u>Bryant R</u>	Autologous FMT trial	THRF Group	2018-2019	\$50,000.00	\$50,000.00	Inflammatory Disease
Wesselingh S, <u>Visvanathan R</u> , Whitehead C, Russell P, Daniel M, Roder D, Stanley A, Griffith L, Karnon J, Miller C, Phillips P, Denson L, Ward L, Gill T, Ratcliffe J, Walters J, Kerrins E (The Healthy Ageing Consortium)	Measuring and Intervening for Health Ageing in South Australia	Premier's Research and Industry Fund (PRIF)	2017-2021	\$4,000,000.00	\$200,000.00	Ageing
Wijesundara D, <u>Gowans E</u> , Robertson S, <u>Grubor-Bauk B</u> , Strestha A	A preclinical evaluation of an innovative DNA based vaccination regimen to protect women of child-bearing age against Zika virus during sexual transmission	Channel 7 Children's Research Foundation	2019-2020	\$100,000.00	\$50,000.00	Drug and Vaccine Development
<u>Wijesundara D</u> , <u>Gowans E</u> , Robertson S, <u>Grubor-Bauk B</u> , Strestha A	A preclinical evaluation of an innovative DNA based vaccination regimen to protect women of child-bearing age against Zika virus during sexual transmission	THRF Group	2019-2020	\$165,000.00	\$82,500.00	Drug and Vaccine Development
Wormald PJ, Maddern G, Vreugde S	A novel medicated resorbable adhesion barrier device for use in abdominal surgery	THRF Group		\$150,000.00	\$75,000.00	Inflammatory Disease; Clinical Sciences, Health Services and Population Health
Wormald PJ, Vreugde S	A new treatment for cystic fibrosis chronic relapsing upper airway infections	Cystic Fibrosis-South Australia		\$60,000.00	\$30,000.00	Inflammatory Disease
Wormald PJ, Vreugde S	A novel treatment for S. aureus recalcitrant chronic rhinosinusitis	Garnett Passe and Rodney Williams Memorial Foundation		\$250,000.00	\$125,000.00	Inflammatory Disease
Wormald PJ, Vreugde S	A novel medicated surgical hydrogel to prevent epidural adhesions post-	NHMRC		\$522,607.00	\$168,000.00	Inflammatory Disease

Investigators	Title	Agency	Years funded	Total awarded	2019-2020	BHI Theme
	laminectomy					
Wormald PJ, Vreugde S, Maddern G	A novel medicated resorbable adhesion barrier device for use in abdominal surgery	NHMRC		\$953,880.00	\$317,960.00	Inflammatory Disease; Clinical Sciences, Health Services and Population Health
Wormald PJ, Vreugde S, Saleh H	A new treatment for cystic fibrosis chronic relapsing upper airway infections	THRF Group		\$250,000.00	\$62,500.00	Inflammatory Disease
Worthley D, <u>Hewett P</u>	Australian trial of Peritoneal Organoid guided therapy to Lengthen Life in patients without Opportunity for cure (APOLLO2)	Cancer Council SA Beat Cancer (Donor funded)	2019-2020 (2 years)	\$382,650.00		Cancer
Young JP, Price T	Personal and family history of Type 2 diabetes and colorectal cancer risk in young adults	THRF Group	2019-2020	\$30,000.00	\$30,000.00	Cancer
<u>Zalewski P</u> , Hodge S, <u>Beltrame J</u> , Murgia C, <u>Tavella R</u>	Role for zinc and ZIP2 in the action of nitric oxide and in vascular protection against cigarette smoke and cardiovascular disease	NHMRC	2018-	\$685,941.00	\$223,443.00	Cardiovascular Disease